SAVANNAH: Phase II Trial of Osimertinib plus Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib

被引：0
|
作者：
Ahn, M. [1 ]
Cantarini, M. [2 ]
Frewer, P. [2 ]
Hawkins, G. [2 ]
Peters, J. [2 ]
Howarth, P. [2 ]
Ahmed, G. [3 ]
Sahota, T. [3 ]
Hartmaier, R. [4 ]
Li-Sucholeiki, X. [4 ]
Oxnard, G. [5 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Astrazeneca, Cambridge, England
[3] Astrazeneca, Quantitat Clin Pharmacol, Early Clin Dev, Imed Biotech Unit, Cambridge, England
[4] Astrazeneca, Waltham, MA USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
MET; Non-Small Cell Lung Cancer; resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-134
引用
收藏
页码：S415 / S416
页数：2
相关论文
共 50 条
  • [21] INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
    Yang, J. C-H.
    Ellers-Lenz, B.
    Straub, J.
    Johne, A.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [22] Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy
    Elghawy, Omar
    Barsouk, Adam
    Reed-Guy, Lauren
    Stalker, Margaret
    Sussman, Jonathan
    Robinson, Kyle
    Kosteva, John
    Singh, Aditi
    Cohen, Roger B.
    Langer, Corey
    Ciunci, Christine
    D'Avella, Christopher
    Sun, Lova
    Marmarelis, Melina E.
    Aggarwal, Charu
    CLINICAL LUNG CANCER, 2025, 26 (02)
  • [23] A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs
    Jiang, R.
    Wang, X.
    Wang, L.
    Huang, D.
    Ding, C.
    Wang, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S346 - S347
  • [24] Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.
    Zhu, Viola Weijia
    Bestvina, Christine M.
    Lopes, Gilberto
    Hamm, John Turner
    Johnson, Melissa Lynne
    Lammers, Philip Edward
    Le, Xiuning
    Marathe, Omkar
    Raez, Luis E.
    Rao, Suman
    Sabari, Joshua K.
    Scheff, Ronald J.
    Tapan, Umit
    Thompson, Jonathan Robert
    Karachaliou, Niki
    Ellers-Lenz, Barbara
    Brutlach, Sabine
    Smit, Egbert F.
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR)
    Elamin, Y. Y.
    Antonoff, M.
    Blakely, C.
    Baggstorm, M.
    Bivona, T.
    Le, X.
    Louie, A. V.
    Doebele, R. C.
    Rusthoven, C.
    Lee, P.
    Govindan, R.
    Swisher, S. G.
    Papadimitrakopoulou, V. A.
    Heymach, J. V.
    Gomez, D. R.
    ANNALS OF ONCOLOGY, 2018, 29 : 547 - 547
  • [26] TATTON: a multi-arm, phase lb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
    Oxnard, G. R.
    Yang, J. C. -H.
    Yu, H.
    Kim, S. -W.
    Saka, H.
    Horn, L.
    Goto, K.
    Ohe, Y.
    Mann, H.
    Thress, K. S.
    Frigault, M. M.
    Vishwanathan, K.
    Ghiorghiu, D.
    Ramalingam, S. S.
    Ahn, M. -J.
    ANNALS OF ONCOLOGY, 2020, 31 (04) : 507 - 516
  • [27] Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report
    Gautschi, Oliver
    Diebold, Joachim
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (04):
  • [28] Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial
    Yang, J.
    Li, A.
    Feng, W. N.
    Li, J.
    Yan, H. H.
    Xu, B. F.
    Zhao, J.
    Jia, Y.
    Tang, K. J.
    Li, Y. S.
    Zhou, C. Z.
    Fan, Y.
    Xu, C. R.
    Sun, Y. L.
    Chen, H. J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S6 - S6
  • [29] A Phase I/II Trial of Dasatinib and Osimertinib in TKI Naive Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Kim, C.
    Liu, S.
    Crawford, J.
    Subramaniam, D.
    Giaccone, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S281 - S282
  • [30] INSIGHT 2: Tepotinib plus osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp)
    Smit, E. F.
    Felip, E.
    Karachaliou, N.
    Ellers-Lenz, B.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2020, 31 : S894 - S894
12345